Nasdaq
$871.00▼ 0.32%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $53.90BShares out 61.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 3d agoPre-market26.10.22 21:206-KKey event#●●●#●●●#●●●
ARGENX SEBullish
argenx reported third-quarter 2026 financial results, achieving $1.721 billion in global product net sales, a 54% increase year-over-year. Driven by strong performance from VYVGART, the company maintained its full-year 2026 guidance for combined R&D and SG&A expenses at approximately $4 billion, which includes costs related to the acquisition of Forte Biosciences.…more
$871.00-0.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.10.19 21:596-KKey event
ARGENX SE
argenx announced that its Phase 3 ALKIVIA study of VYVGART Hytrulo for autoimmune myositis met its primary endpoint. The study showed a 15.4-point greater improvement in the Total Improvement Score (TIS) compared to placebo at week 52, with results to be presented at the ACR Convergence 2026 on November 11.…more
$871.00-0.32%vs prev closeView filingShare - 10.8Pre-market26.10.08 19:016-KKey event
ARGENX SE
argenx announced positive Phase 2 results for its celiac disease candidate FB102, with plans to advance into Phase 3 development. Conversely, the company is discontinuing the Phase 3 UNITY study of efgartigimod SC for Sjögren's disease after an interim analysis indicated the study would fail to meet its primary endpoint.…more
$871.00-0.32%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoOvernight26.10.22 14:22#●●●#●●●
argenx Q3 Revenue Beats Estimates, EPS Misses Slightly
argenx reported Q3 revenue of $1.751 billion, exceeding analyst expectations and marking a 52% year-over-year increase. However, the company's quarterly EPS of $7.80 fell slightly short of the $7.83 consensus estimate.…more
$871.00-0.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoOvernight26.10.22 14:00
●●●●●●●● ●●●●● ●●●●●●
argenx achieved $1.7 billion in global product net sales for the third quarter of 2026, marking a 54% year-over-year increase driven by strong VYVGART performance. The company continues to advance its immunology pipeline and expand indications to support long-term growth.…more
$871.00-0.32%vs prev close - 6d agoPre-market26.10.19 21:00
●●●●●●●● ●●●●● ●●●●●●
argenx reported that its Phase 3 ALKIVIA study demonstrated clinically meaningful improvements in patients with autoimmune myositis compared to placebo. The data will be presented at the ACR Convergence 2026, supporting the potential for future regulatory approval.…more
$871.00-0.32%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report